Nephrology

The VersiPD Cycler System is expected to be available in the US in 2022.

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

No specific inflammatory pathway was considered causative to long-term mortality in kidney transplant recipients.

Late use of steroids among patients with AIN shows now indication of further recovery and poses an additional risk of exposing patients to adverse effects.

Dr. Jabbour discusses unmet needs in diabetes care and starting insulin therapy.

Team-based care shows the reduction of multiple risk factors, attainment of multiple treatment targets, and empowerment among high-risk patients with DKD.

The costs related to Medicare for OACC increased by about 4% between 2012-2017 for patients with end-stage kidney disease for kidney transplantation.

When combined with corticosteroids, the oral therapy appeared to be as effective as IVCY with a more favorable safety profile.

The agency cited an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and increased risk of drug-induced liver injuries.

The phase 3 trial was stopped following a formal interim assessment that met pre specified criteria for positive efficacy in patients with chronic kidney disease.

The use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality compared to DPP-4 inhibitors.

The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.

The treatment was comparable to darbepoetin alfa in treating patients with chronic kidney disease who were not undergoing dialysis.

Patients who receive a solid organ transplant and develop CDI are at an increased risk for an acute kidney injury.

The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was −11.0 mm Hg in the chlorthalidone group and −0.5 mm Hg in the placebo group.

The treatment resulted in a significant reduction of proteinuria from baseline in 34% of trial participants.

Patients with sickle cell disease often suffer from acute kidney injuries and chronic kidney disease.

The DCRM Task Force recommendations were described as first-of-its-kind guidance for patients with overlapping diabetic, cardiorenal and metabolic disease.

Data show hemoglobin level of SGLT2 inhibitor users were higher at an eGFR above >15 mL/min/1.73m2 compared to non-users.

After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.

There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.

The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.

The adjusted change in 24-hour systolic blood pressure was -11.0 mm Hg in the chlorthalidone group and -0.5 mm Hg in the placebo group.

Though immunogenicity responses to the vaccine were lower in dialysis patients, the lower response rate was less apparent in second doses.

Patients with Crohn's disease often also suffer from kidney dysfunction.

The new PDUFA date for Nefecon will be December 15, 2021.